In a patient with chronic kidney disease stage 3B (eGFR 30–44 mL/min) and binge‑eating disorder, are glucagon‑like peptide‑1 receptor agonists beneficial?

GLP-1 Receptor Agonists Are Beneficial in CKD Stage 3B with Binge Eating Disorder

Yes, GLP-1 receptor agonists are beneficial for patients with CKD stage 3B (eGFR 30-44 mL/min) and binge eating disorder, offering dual advantages: kidney and cardiovascular protection from the CKD, plus reduction in binge eating behaviors from the eating disorder.

Rationale for Use in CKD Stage 3B

Kidney and Cardiovascular Benefits

GLP-1 receptor agonists are explicitly recommended for patients with type 2 diabetes and CKD stage 3B who have not achieved glycemic targets despite metformin and/or SGLT2 inhibitors, or who cannot use these medications 1. The evidence shows:

• Reduced albuminuria and slower eGFR decline across cardiovascular outcomes trials 2
• Reduced major adverse cardiovascular events (MACE), with notably greater benefit in patients with eGFR <60 mL/min/1.73 m² compared to those with higher eGFR 2
• No dose adjustment required for most long-acting GLP-1 RAs (dulaglutide, liraglutide, semaglutide) in CKD stage 3B 2, 1

The preferred agents are dulaglutide, liraglutide, and injectable semaglutide as they have demonstrated cardiovascular benefits in large outcome trials 2, 1.

Specific Benefits for Binge Eating Disorder

GLP-1 receptor agonists reduce binge eating behaviors with moderate effect sizes 3. A systematic review and meta-analysis found:

• Moderate reductions in binge eating (standardized mean difference -0.23,95% CI -0.36 to -0.10) 3
• Reduced loss of control eating (mean difference -18.38,95% CI -23.34 to -13.43) 3
• Lower eating disinhibition (standardized mean difference -0.54,95% CI -0.90 to -0.18) 3
• Effects were larger in trials enrolling participants with diagnosed binge eating disorder 3

GLP-1 RAs may be preferentially used in patients with obesity, type 2 diabetes, and CKD to promote intentional weight loss 1, 4, which aligns perfectly with managing both conditions simultaneously.

Practical Implementation

Drug Selection and Dosing

Choose semaglutide, liraglutide, or dulaglutide as first-line options 1:

• Semaglutide: 0.5-1 mg weekly (injection) or 3-14 mg daily (oral) - no dose adjustment needed 1
• Liraglutide: 1.2-1.8 mg daily - no dose adjustment needed 1
• Dulaglutide: 0.75-1.5 mg weekly - no dose adjustment needed, can be used with eGFR >15 mL/min/1.73 m² 1

Titration Strategy

Start low and titrate slowly to minimize gastrointestinal side effects 1, 4. This is particularly important because:

• Nausea, vomiting, and diarrhea occur in 15-20% of patients with moderate-to-severe CKD 2
• These symptoms usually abate over several weeks to months with dose titration 2
• Slow titration also helps with tolerability in binge eating disorder 3

Key Monitoring Points

1. Monitor eGFR when initiating or escalating doses, especially if patients develop severe gastrointestinal reactions 5
2. Assess for hypoglycemia risk if used with insulin or sulfonylureas - may need to reduce doses of these agents 1, 4
3. Track binge eating behaviors and weight loss as dual therapeutic targets
4. Watch for volume depletion if patient is on diuretics, though this is less of a concern than with SGLT2 inhibitors

Important Caveats

Contraindications and Precautions

• Avoid in patients at risk for thyroid C-cell tumors (e.g., multiple endocrine neoplasia), pancreatic cancer, or pancreatitis based on theoretical risks 2
• Do not combine with DPP-4 inhibitors 1, 4
• Gastroparesis is a relative contraindication due to delayed gastric emptying effects 6

Gastrointestinal Side Effects Management

The most common side effects are gastrointestinal 2:

• Start with low doses and titrate upward slowly 1
• Reduce meal size 6
• Limit alcohol and carbonated drinks 6
• Avoid high-fat diet 6

Combination Therapy Considerations

GLP-1 RAs can be safely combined with SGLT2 inhibitors for additive kidney and cardiovascular benefits 4. If the patient is already on an SGLT2 inhibitor and metformin but not meeting glycemic targets, adding a GLP-1 RA is the recommended next step 2, 1.

Clinical Bottom Line

For a patient with CKD stage 3B and binge eating disorder, initiate a long-acting GLP-1 receptor agonist (preferably semaglutide, liraglutide, or dulaglutide) without dose adjustment, starting at the lowest dose and titrating slowly. This addresses both the kidney disease (reducing cardiovascular events, slowing eGFR decline, reducing albuminuria) and the eating disorder (reducing binge eating episodes and promoting weight loss). The dual benefit makes GLP-1 RAs uniquely suited for this clinical scenario, with the caveat that gastrointestinal side effects require careful monitoring and slow titration.